Stopping Semaglutide: What Happens
STEP-4 showed two-thirds of weight returns within a year of stopping semaglutide. Here's why, what tapering does (and doesn't), and the indefinite-use question.
Updated May 6, 2026 · 6 min read
The question of stopping semaglutide is the question most users haven't fully thought through when they start. The drug is genuinely effective, but the gains are largely dependent on continued use — and the data on what happens when you stop is some of the most consistent in obesity medicine.
This isn't a moral judgment. It's biology, and it's worth understanding before you commit either to starting or to stopping.
What the trials actually show
The most-cited number comes from the STEP-4 trial, published in JAMA in 2021. The design:
- Participants took semaglutide 2.4 mg for 20 weeks (the titration period plus a stretch at maintenance)
- Then half were randomized to continue on the drug, the other half switched to placebo
- Both groups received lifestyle support throughout
- Followed for 48 more weeks
The result: the placebo group regained roughly two-thirds of their lost weight by week 68. The continuing-treatment group kept losing.
A separate follow-up of STEP-1 participants tracked weight one year after the trial ended. They had regained about two-thirds of their weight loss as well, despite ongoing lifestyle counseling.
This is the headline finding. For the other side of the timeline, see how long does semaglutide take to work.
Why weight comes back
Three biological mechanisms drive the regain:
1. Appetite returns
This is the dominant factor. Semaglutide suppresses hunger and "food noise" by sustaining GLP-1 receptor activation. When the drug clears (about 4 weeks after the last dose), your appetite returns to roughly baseline — and for many users, slightly above baseline as the body responds to recent weight loss with increased hunger signals.
The timeline for appetite return:
- Week 1–2 off: Subtle. Most users feel only marginal change.
- Week 3–4 off: Noticeable. "Food noise" comes back. Portions feel smaller.
- Month 2 off: Substantial. Hunger between meals, cravings, the impulse to snack — all back.
- Month 3–6 off: Most users describe baseline appetite as fully restored, sometimes with a "rebound" feeling.
2. Gastric emptying speeds back up
Semaglutide slows how fast food leaves your stomach, which is part of why small meals feel filling and stay filling for hours. Once the drug is out of your system:
- Stomach empties at normal speed
- Fullness signal shortens
- Meals don't "stretch" the way they did
- More frequent eating feels natural again
3. Metabolic adaptation
This is the bitter cherry on top. After significant weight loss, resting metabolic rate drops more than expected for the new body weight — a phenomenon called metabolic adaptation that's been documented in obesity research for decades.
This means: even if you ate the same number of calories you ate at your lower weight, you'd slowly regain. Add in returning appetite, and the path of least resistance is regain.
Tapering: does it help?
There's no clinical evidence that tapering semaglutide before stopping reduces regain. The drug clears at a predictable rate regardless of whether your last dose was 2.4 mg or 0.5 mg — the half-life is the same.
What tapering can do:
- Soften the side-effect transition. Some users report a brief stretch of mild GI symptoms when stopping abruptly from a high dose, which a taper can smooth out.
- Give you a runway to build new habits before appetite returns in full.
- Surface lifestyle gaps early. Going from 2.4 mg to 1.0 mg is a partial preview of what off-drug appetite will feel like.
If you're going to taper, a typical approach is to step down through your previous titration steps, 4 weeks per step, in reverse: 2.4 → 1.7 → 1.0 → 0.5 → 0 mg. But cold-turkey discontinuation isn't dangerous; the data suggests it just isn't significantly different from a taper for the regain question.
For the dose ladder, see semaglutide dosing schedule.
Strategies that work for some people
Not everyone regains the full two-thirds. The subset that maintains more of the loss tends to share:
- Resistance training during weight loss. Preserving lean mass blunts metabolic adaptation. Hard to start after the fact.
- Higher protein intake. 0.7–1.0 g per lb of goal body weight, sustained.
- Tight food-tracking habits built during the on-drug phase, continued off.
- Intermittent or low-dose maintenance — see below.
- A clear behavior change (cutting alcohol, eliminating ultraprocessed snacks, etc.) that survives the appetite return.
The honest reading: a minority of users keep most of their loss off the drug. The majority don't, despite their best efforts. This isn't willpower failure — it's biology.
For more on the alcohol piece specifically, see semaglutide and alcohol.
The indefinite-use question
Increasingly, the medical conversation has shifted from "lose weight on semaglutide and stop" to "treat obesity as a chronic condition the same way we treat hypertension." The framing argues:
- We don't expect blood pressure to stay normal after stopping antihypertensives
- We don't expect cholesterol to stay low after stopping statins
- Obesity has similar relapse biology
- So semaglutide may be a long-term medication for many users, not a short course
Counterpoints worth weighing:
- Long-term safety data is improving but the longest cohorts are still well under 10 years
- Cost is significant — a multi-decade course of brand-name semaglutide is expensive even with insurance
- Side effects, while usually tolerable, are still side effects — see the timeline
- Lifestyle interventions are still the most-evidenced approach for some patients, even if average results are smaller
The "right" answer depends on individual risk factors, comorbidities, and how the body responded.
Maintenance dosing
A middle path some clinicians use: lower-dose long-term maintenance after reaching goal weight. For example, dropping from 2.4 mg to 1.0 mg or 0.5 mg as a "maintenance" dose to preserve appetite suppression without the full weight-loss intensity.
The evidence base for this is thinner than for full-dose maintenance — the trials weren't designed to test it — but it's an increasingly common clinical practice and may offer most of the regain protection at lower cost and side-effect burden.
Stopping during pregnancy or planned pregnancy
Semaglutide should be discontinued at least 2 months before a planned pregnancy per the FDA label, due to its long half-life. This is a non-elective stop. Discuss with your prescriber.
What stopping looks like, week by week
| Week off | What's typical |
|---|---|
| 1 | Almost nothing different |
| 2 | Subtle appetite uptick |
| 3–4 | "Food noise" returning, fullness feels shorter |
| 5–8 | Appetite substantially back, weight may start creeping |
| 9–16 | Notable regain begins for many users |
| 6 months | About half of lost weight typically back |
| 12 months | About two-thirds of lost weight typically back |
This is averages. Individual variation is real, but the trend across populations is robust.
What to do if you've stopped and want to restart
Restart logic depends on how long you've been off. See missed dose of semaglutide — the same restart-after-extended-break framework applies. For most people who have been off more than 4 weeks, the path is restarting from a lower titration step rather than jumping back to maintenance.